# WHAT IS WRONG WITH CURRENT DIALYSIS

Nathan W. Levin M.D.

Mount Sinai Icahn School of Medicine

#### The Dialysis Prescription

The detailed biochemical basis of the dialysis prescription remains obscure—other than for H<sup>+</sup>, K<sup>+</sup> Na<sup>+</sup>, H2O, Ca<sup>++</sup> and PO<sub>4</sub> - despite 45 years of clinical experience with this therapy.

Urea Kinetic Modeling has been successfully used to define <u>clinical outcome equivalent doses</u> for low efficiency, virtually continuous peritoneal dialysis (CAPD) and high efficiency thrice weekly Hemodialysis (HEMO)

## Daugirdas II

Kt/V = -IN (R - 0.008 x t) + (4-3.5 x R) x UF/BW

Approximation for Kt/V

# Dose is based on urea kinetics because that is where the evidence is

#### DOSE OF AN INDIVIDUAL DIALYSIS

Three expressions of the dose:


```
URR = 70 Pre/Post BUN Rx trial and error
    Not corrected for Qf and/or rate
spKt/V = 1.4 Not corrected for rate & rebound
eKt/V = 1.2 Corrected for rate & rebound
```

#### **BAD DIALYSIS**

- NOT reaching the correct Kt/V
- NOT reaching the appropriate protein intake


#### Why do some units have poor Kt/Vs

- Prescription incorrect for Body V
- Poor accesses are tolerated
  - Low K
- Patient end their treatment early
  - Low t
- Prescription not followed
  - blood flow not correct from initiation
  - t wrong
  - wrong dialyzer
  - wrong dialysate flow
  - access inadequate or recirculation
  - clotting of dialyzer
  - blood drawn incorrectly



Solution of the single pool urea kinetic model for pre dialysis mid week BUN as a function of NPCR and spKt/V shows a family of spKt/V curves relating BUN to NPCR.

#### Limits of Dialysis Efficiency



Efficiency of toxin elimination decreases exponentially when eKt/V of a single treatment is increased

#### Association Between Higher Dose and Relative Overall Risk of Mortality for Males and Females Among Three Studies

	Relative Risk of Mortality for Higher <i>vs.</i> Lower Dose <sup>1</sup> Female Male				Dose Effect by Gender <sup>2</sup>
	RR	p-value	RR	p-value	p-value
HEMO Study <sup>3</sup>	0.81		1.16		<0.01
DOPPS (per 0.37 eKt/V) <sup>4</sup>	0.80	<0.001	0.93	0.23	80.0
CMS (URR >75% vs. 70%-75%)	0.85	<0.0001	0.96	0.22	0.003


<sup>4</sup> Linear estimate of RR=0.94 per 0.1 eKt/V for females and RR=0.98 per 0.1 eKt/V for males applied to a difference of 0.37 eKt/V (equals average difference in HEMO Study groups).



<sup>&</sup>lt;sup>4</sup> P-values test whether high dose is associated with a reduction in mortality for each sex.

<sup>&</sup>lt;sup>2</sup> Tests whether the RR for females equals the RR for males. A significant difference indicates that high dose is associated with a larger reduction in mortality for females than for males.

<sup>3</sup> Compares average eKt/V of 1.53 and 1.16, and average URR of 75.2% and 66.3% [1].



The stdKt/V model provides a template to quantitatively describe dialysis treatment schedules over a wide ranges of intensity and frequency.

#### Dialysis Times too short:

This results in inability to remove intradialytic weight load causing hypertension, cardiac failure and increased hospitalization and mortality

High ultrafiltration rates result in intradialytic hypotension and cardiac, cerebral, gut and renal ischemia with loss of residual kidney function

Short times are selected ccurs because of need to control duration of shifts

# INTRA DIALYTIC HYPOTENSION with organ ischemia


#### Dialysis not frequent enough

Especially during the long interdialytic period, fluid accumulation and increased cardiac strain occur resulting in need for higher ultrafiltration rates

FHN showed improvement in left ventricular hypertrophy with daily dialysis

#### Death/LVM Composite Outcome:






# Change in LV Mass




**FHN Daily Trial** 



Change in LV Mass

# Death/PHC Composite Outcome ... FHN






# Change in PHC Score




**FHN Daily Trial** 




Change in PHC Score

# Main Secondary Outcome Results:



#### Time to First Vascular Access Intervention





#### **Adverse Events**



Outcome	3x-Per-Week (n=120) 1	6x-Per-Week (n=125) 1	Hazard Ratio (95% CI)	p_ value
Deaths	9	5		
All hospitalizations	114 (47)	109 (58)	0.88 (0.60, 1.28)	0.50
Non-access hospitalizations	90 (44)	79 (47)	0.80 (0.53, 1.21)	0.30
Cardiovascular hospitalizations	15 (12)	17 (15)	0.83 (0.44, 1.59)	-
Infection hospitalizations	27 (20)	27 (23)	0.83 (0.49, 1.40)	-
Access hospitalizations	24 (14)	30 (20)	0.99 (0.54, 1.82)	0.97
All vascular access interventions	65 (29)	95 (47)	1.35 (0.84, 2.18)	0.22
Failures	23 (15)	19 (15)	0.71(0.35, 1.44)	0.35
Other procedures	42 (21)	76 (38)	1.71(0.98, 2.97)	0.058
Hypotensive episodes	470 (87)	724 (99)	-	-
Hypokalemia (potassium <3.0 mEq/L)	0 (0)	0 (0)	-	-
(potassium <3.5 mEq/L)	6 (5)	13 (8)	-	0.57
Hypophosphatemia (phosphorus <2.17 mg/dL)	9 (7)	15 (9)	-	0.80

<sup>&</sup>lt;sup>1</sup>Total numbers of events and (numbers of patients with events) during the follow-up the period.



#### **FHN Daily Trial Summary**

Compared to conventional 3x-per-week hemodialysis, more frequent hemodialysis resulted in:

- Statistically significant improvements in the co-primary composite outcomes of death/LVM and death/PHC
- Improved control of hypertension and hyperphosphatemia
- No significant effect on Trail Making B, Beck Depression Inventory, ESA dose and albumin
- Lower interdialytic weight gain
- More vascular access interventions

The overall benefit of daily dialysis was shown by satisfying the pre-study requirement for favorable effects on both coprimary outcomes. This was accompanied by more vascular access interventions.

 Cardiovascular disease is not well controlled despite being the major cause of mortality

Left ventricular failure and diastolic dysfunction are very common in dialysis patients.

Problems include lack of sodium restriction and volume control withfluid overload. Use of cardiac drugs is often poor and in particular the underutilization of non-dialyzable beta-blockers. The poorer outcome with dialyzable beta-blockers may be due to the rapid reduction of the level of the drug in an environment which encourages the development of ventricular arrhythmias associated with increased sympathetic tone, large hemodynamic and electrolyte fluxes and marked ischemic heart disease with ventricular hypertrophy.

ACE inhibitors and ARBS appeared have more effect on dialysis patients.

- Uremic toxins are inadequately removed
- The adequacy of dialysis is usually assessed by the relationship of urea removal in relationship to body volume(Kt/V)
- The latter does correlate with outcomes, but the majority of uremic toxins is not removed by current dialyzers which are limited by the pore size of the membranes used.
- New approaches include interference with binding of small molecular weight compounds, thus allowing their removal by dialysis.
- In the future might be online plasma filtration with adsorption or binding of uremic toxins.

#### Dialysis costs are high

To a larger degree then with most medical treatments chronic dialysis has been commercialized. The major proportion of the cost per patient is hospitalisation with infection and fluid overload being the most important factors. The alternatives, which are less costly, include transplantation, peritoneal dialysis and home dialysis, which all result in outcomes which are on average better then in center dialysis. Obviously personal preference is the most relevant factor once choices are possible

#### Dialysis in chairs

Countries such as China, Japan, France and Italy dialyze their patients in beds. These countries all have better survival/ Other countries such as, United States, Germany and to a large extent UK dialyze their patients in chairs which is associated with pooling of fluid in the legs and increased sympathetic tone.

It remains to be seen whether the lower mortality in bed dialyzed patients is due to position or because the patients are differentWhat do you think

#### Inadequate referral to transplantation

The percentage of readily transplantable patients on a list, should a donor become available, is a reflection of the competence and organization of the facility.

Success requires advocacy with patient and family, participation of transplant surgeons and efficient immunological services. Live donors need to be encouraged

Gebate exists concerning the use of paid donors. A recent challenge to current thinking is to pay suitable donors amounts of plus/minus \$50,000 followed by life-long guaranteed insurance. The value to society according to its calculations is large with benefits to USA tax payers of 12 billion dollars a year

 Volume control in patients is generally poor with most patients being hypertensive (USA)

Volume control is difficult because sodium restriction is not easily accepted by patients nor properly indoctrinated by dialysis staff. A target dry weight is often erroneous and based on clinical information such that patients are variously hypertensive, hypotensive in cardiac failure or dehydrated

New bioimpedance techniques provide dry weight information. Lengthening dialysis duration makes it easier to attain dry weight. Hypertension and hospitalization diminish and patients live longer.

# Background


- We need an accurate method to estimate normal fluid status (NFS) in dialysis patients.
- Continuous calf bioimpedance techniques are accurate to estimate dry weight (DW) but requires constant body position during dialysis.
- The questions are
- 1. Can the calf present the total body in estimating fluid status and body composition;
- 2. Is it possible to predict DW with the calf method without continuous measurement?

# Calf bioimpedance measurement





- Resistance (R) represents fluid volume in the calf.
- Resistivity (ρ = R\*A/L) is calculated by R times area of calf (A) within a distance L.
- BMI: body mass index

#### How to determine Dry Weight with cBIS



Estimation of muscle mass (MM) and total adipose tissue (TAT) with calf bioimpedance






 $MM_{CBM}$  =-0.103\*cRi+30.58\*Height+0.159\*weight-0.098\*Age-28.736, TAT<sub>CBM</sub>= 0.13\*cRi-0.142\*CA +2.43\*BMI+0.129\*Age-44.33

17th International Conference on Dialysis Advances in Kidney 2015

# Correlations of change in body weight and change in CNR in different stage of FO



17th International Conference on Dialysis Advances in Kidney 2015

#### **BAD DIALYSIS**

Not taking into consideration the dialyzability of drugs whether too much or too little

# b-Blocker Dialyzability and Mortality in Older Patients Receiving Hemodialysis

Some β-blockers are efficiently removed from the circulation by hemodialysis ("high dialyzability") whereas others are not ("low dialyzability"). This characteristic may influence the effectiveness of the βblockers among patients receiving long-term hemodialysis. To determine whether new use of a high-dialyzability β-blocker compared with a lowdialyzability β-blocker associates with a higher rate of mortality in patients older than age 66 years receiving long-term hemodialysis, we conducted a propensity-matched population-based retrospective cohort study using the linked healthcare databases of Ontario, Canada. The high-dialyzability group (n=3294) included patients initiating atenolol, acebutolol, or metoprolol. The low-dialyzability group (n=3294) included patients initiating bisoprolol or propranolol. Initiation of a high- versus low-dialyzability β-blocker was associated with a higher risk of death in the following 180 days (relative risk, 1.4; 95% confidence interval, 1.1 to 1.8; P<0.01). Supporting this finding, we repeated the primary analysis in a cohort of patients not receiving hemodialysis and found no significant association between dialyzability and the risk of death (relative risk, 1.0; 95% confidence interval, 0.9 to 1.3; P=0.71)


Table 2.

All-cause mortality (conditional logistic regression model)

<u>Variable</u>	<u>Patients</u>	(n) No. of Events (%)	RR (95% CI)	P Value
Hemodialysis cohort				
High-dialyzability b-blockers	3294	182 (5.5)	1.4 (1.1 to 1.8)	<0.01
Low-dialyzability b-blockers	3294	135 (4.1)	1 (referent)	
Nondialysis cohort				
High-dialyzability b-blockers	13,586	186 (1.4)	1.0 (0.9 to 1.3)	0.71
Low-dialyzability b-blockers	13,586	179 (1.3)	1 (referent)	

# Q:Why are outcomes different? A:Patient characteristics Dialysis technical problems


# There must be more than "Practice Patterns"



J Am Soc Nephrol 2003; 14:3270-3277


## All-cause Mortality by Race in USA Cox Survival Model, 1 Year Follow-Up (01/03 - 01/04)

#### Adjusted for age, gender and diabetes



# Atherosclerosis related CV death rate Dialysis vs. General Population

23 countries, per 1000 population year




# Lower Relative Death Rate in Asian Dialysis Patients

Age-adjusted relative risk of mortality for dialysis patients higher in USA (n=150.862) than Japan (n=66.244)


Are the differences in survival reported between Japanese and US populations accounted for by differences in the US delivery system?

25-35% lower mortality risk for Asian-American dialysis patients than for Caucasian-American




Held et al Am J Kidney Dis 1990

Wong et al. Kidney Int 55;2515-2523, 1999



Comparison of FMC data to HEMO Results



Body mass index (kg/m²)

#### **BAD DIALYSIS**


 Water systems that reliably have no chemical contaminants, no bacteria or viruses

## Water Treatment for Hemodialysis

"It is not exaggerated to state that inadequate water treatment is one of the gravest risks posed to the health of the patient on dialysis."

PR Keshaviah

## Water Purification System



#### Overview

#### Water

- Water treatment- Why and How
- Consequences of inadequate water treatment

#### Water contaminants

- Contaminants in ground or surface water
  - Chemical contaminants
    - Nitrates, sulphates, calcium, magnesium, trace metals, heavy metals, pesticides
  - Bacterial contaminants
    - Excreted bacterial pathogens
      - e.g faecal bacteria from animals
    - Pathogens growing in water supplies
      - e.g cyanobacteria
- Chemicals added during municipal treatment

Water delivered to the consumer complies with EPA requirements in respect of contaminant levels but is unsuitable for use in dialysate preparation unless subjected to further treatment

## Why treat water further?

- Typically a dialysis patient is exposed to 360 liters of water per week, i.e 25 times more than the average person drinks in a week
- A dialysis patient is exposed to more water in three years than the average person in a lifetime
- Transfer of contaminants from drinking water is prevented in the gut, but for dialysis patients blood is separated from water used in the preparation of dialysis fluid by a semi permeable membrane.

## Regulatory aspects of water quality

- Standards define the acceptable contaminant levels within the water used for dialysate preparation
  - AAMI water quality standards RD 62: 2001
  - CMS (HCFA) conditions for coverage of ESRD services require compliance with 103 V tags

#### Consequences of inappropriate water quality

- Nearly every water contaminant has the ability to cause problems in ESRD patients.
   Over a long period it may not be easily distinguishable from problems arising from ESRD
- Chemical contaminants
  - Aluminium
  - Chlorine and chloramine
- Bacterial contamination

## Three Deaths Associated With Excess **Aluminum in Dialysate**

Three recent deaths among patients on dialysis have been tied to excessive serum aluminum levels



## Patient Injury in Hemodialysis

1992 – 3 Patients die in Chicago. Fluoride poisoning

1996 - 60 patients die in Caruaru, Brazil.

Water system contaminated with high levels of blue green algae

## Patient Injuries in Hemodialysis

1996 - 9 patients die in the Netherlands Antilles.

High levels of aluminum in water

1998 - 3 patients die in Hong Kong Disinfectant contaminated water.

## Patient Injuries in Hemodialysis

2000 - 2 patients die, 17 injured in Youngstown, Ohio.

High levels of bacteria found in the water distribution loop

## Dialysate

- 1992 3 deaths associated with excess aluminum in dialysate
- 1995 Patient dies hours after dialysate accident
- 2008 22 Patients hospitalized with anemia after undetected chloramine breakthrough

No matter how good the source water supply is, it cannot be considered suitable for dialysis without further purification.


## Aluminium

### Aluminium


- Regulatory standard for drinking water
  - -0.2mg/l [0.2ppm]
- Desirable level in water used for the preparation of haemodialysis fluid
  - 0.01 mg/l [0.01 ppm]
- Principal mode of removal
  - Reverse osmosis
  - Some may also be removed by deionizer

#### **EFFECT OF TREATMENT ON WATER ALCONTENT**

Plarkinson IS et al. J. Clin Pathol 34:1285-1294, 1981.



#### EFFECT OF pH ON ALUMINUM IN WATER



## Chlorine and Chloramine

#### Chlorine and chloramine

- Chlorine (CI)
- Chloramine (C<sub>7</sub>H<sub>8</sub>ClNO<sub>2</sub>S.Na)
  - Condensation products of chlorine and ammonia
- By products
  - Trihalomethanes (THM) and Haloacetic Acids (HAA5) are formed when chlorine or other disinfectants react with naturally occurring organic and inorganic matter in water.
  - Their presence in water is regulated as both have demonstrated carcinogenic activity in laboratory animals and linked to an increased risk of miscarriage.



## Three Deaths Associated With Excess **Aluminum in Dialysate**

Three recent deaths among patients on dialysis have been tied to excessive serum aluminum levels leached in through a dialysis unit's dialysate delivery system, according to the Food and Drug Adminis-




#### Chloramine and chlorine removal from water

- Carbon filtration is the only effective method for the removal of chlorine and chloramines
- Desirable features of carbon used
  - Empty bed contact time [EBCT] 10 minutes minimum
  - Adsorptive capacity [lodine number] 900-1000
- Requires worker polisher configuration for optimum effect
- Effectiveness of carbon is dependent on a range of factors, but it is estimated that 200kg of carbon is required for 1000liters of water

# Factors that Promote Bacterial Growth in Dialysis Fluid Systems

#### **Favorable environment**

- Nutrients
- Water
- Room temperature
- No flow
- No disinfection
- Uneven surfaces/joints (biofilm formation)



# Development and consequences of biofilm within the pipework

- Bacteria enters system
- Attaches to surface
- Multiplies and spreads
- Protective surface layer develops
- Fragments released
- Inflammatory response in patients



# Minimization of bacterial products in the dialysis fluid

- Prevention of the formation of biofilm
- Monitoring
- Introduction of bacterial filters

#### Monitoring and control


- Disinfect regularly
  - Prevents the development of bacterial growth
- Monitor regularly
  - Use appropriate methods
- Maintain records and QA charts

## **Monitoring Frequency**


- Daily
  - Chlorine and chloramine ( every shift)
  - Water softener
  - -RO
- Weekly
  - Cultures for bacteria
  - LAL for endotoxin
- Monthly
  - All dialysis machines
- 6 monthly
  - Feed water quality

### **Filtration**


# Filters incorporated into new generation of proportionating systems to minimize endotoxin exposure




## Ultrafilters Remove Bacterial Products by Size Exclusion and Adsorption



#### **Ultrafilters Reduce Bacterial Counts**



## Reduced Microinflammation prospectively assessed in vivo by analysis of CRP



Schindler et. al, Clin Nephrol 2000

### Filtered Fluid Reduces Inflammation

	standard fluid	filtered fluid	p<0.05
fluid quality (CFU/ml)	85 <del>→</del> 93	90 ⇒ 0	#
IL-6 (pg/ml)	34 🛶 40	38 \Rightarrow 18	#
CRP (mg/dl)	1.2 \Rightarrow 1.0	1.3 👄 0.6	#
Hb (g/dl)	10.0 \Rightarrow 10.1	10.1 \Rightarrow 10.2	
rHuEPO (U/kg/week)	96 👄 92	92 👄 64	#

# Filtered Fluid Reduces Inflammation and Improves Nutritional Markers

	standard	ultrapure	
	fluid	fluid	p<0.05
fluid quality (CFU/ml)	60 🛶 42	63 ⇒ 0	* #
IL-6 (pg/ml)	21 \Rightarrow 24	19 ⇒ 13	* #
CRP (mg/dl)	0.9 \Rightarrow 1.1	1.0 👄 0.5	* #
dry weight (kg)	73.5 🖚 74.1	72.1 \Rightarrow 76.3	*
circumference (cm)	26.9 \Rightarrow 26.5	26.3 👄 27.5	*
albumin (g/dl)	3.5 \Rightarrow 3.6	3.6 \Rightarrow 3.9	*

## Summary for water

- Water quality is an important contributor to morbidity and outcomes in ESRD patients
- Detailed attention to these aspects needs to be paid to ensure optimal outcomes associated with treatmens


## Effect of body size

## Standard Kt/V

# A Fable The Hare and the Tortoise (Aesop, 650 BC)

Aesop's message: The slow but continuously moving turtle can travel as far and as quickly as the very much faster but intermittently sleeping rabbit.

#### N dialyses/wk



The model fits the adequate dose for CAPD equal to the adequate dose for thrice weekly HD.

#### **Case History – for discussion only**

The KoA of a dialyzer is 1200 ml/min; the blood flow prescribed is 350 ml/min; treatment time is 210 min; dialysate flow is 500 min/min. The patient urea distribution volume is 30 liters

**UKM** results are:

eKt/V = 0.8

Urea distribution volume 36 l

Access flow 450 ml/min

The arterial pre-pump pressure is – 368 mmHg

Describe the situation in one sentence.

## **Baseline Characteristics**




#### **FHN Daily Trial**

Factor	All Patients (n=245)	3x-Per-Week (n=120)	6x-Per-Week (n=125)
Age (years) (mean ± SD)	50.4 ± 13.9	52.0 ± 14.1	48.9 ± 13.6
Female (%)	38	39	38
Race			
Black (%)	42	44	39
White (%)	36	38	34
Other (%)	22	18	26
Diabetes (%)	41	42	40
ESRD vintage (years)			
< 2 (%)	16	17	16
2 – 5 (%)	39	42	35
> 5 (%)	45	41	49

## Separation in Treatment Parameters between Groups FHN Daily Trial





Urea Kinetic Modeling (UKM) is simply the formal mathematical description of urea mass balance

Urea Input = Urea Removal

In steady state, ie, chronic renal failure,

Generation of Urea = Removal of Urea

Rarely measure Generation

Rarely measure Clearance

Generation

Clearance

Always measure BUN